Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | 3004299 | PO / MO |
The patient took Vivotif after having some food; Case reference number US-BN-2025-001430 is a spontaneous case initially received from a nurse via Communication (reference number: USBAV25-2088) on 20-Aug-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 19-Aug-2025, the patient took the first dose of Vivotif after having some food (batch number: 3004299), at unknown dose, orally for indication pre travel (explicitly coded as: 'product administration error'). At the time of the initial report, it was unknown if the patient experience any of adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age took the first dose of Vivotif after having some food, for indication pre travel, which is considered as product administration error. It was unknown if the patient experienced any of adverse events due to Vivotif. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took the first dose of Vivotif after having some food, for indication pre travel, which is considered as product administration error. It was unknown if the patient experienced any of adverse events due to Vivotif. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None